Business software company Oracle has agreed to acquire Relsys, a provider of drug safety and risk management applications, for an undisclosed amount. The deal is expected to close by summer.

Relsys, which supports adverse event reporting, risk management and data analysis for drug and medical device developers and contract research organizations, will becomes a part of Oracle’s Health Sciences Global Business Unit.

Through this acquisition, Oracle hopes to deliver a suite of software applications that supports end-to-end drug safety processes across clinical development, post-market surveillance and patient care.

“The health sciences industry is increasing investments in software that provide greater transparency into drug safety and help improve the overall safety of therapies,” said Neil de Crescenzo, senior vice president and general manager of Oracle Health Sciences, in a company statement.